Hydrochloric Acid

Hydrochloric Acid

SCHEMBL333583

C#CCNC1(OC(=O)NCC)CCCc2ccccc21.Cl

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 1/20 0.39
CHRNA7 known ✓ P36544 1/20 0.34
SIGMAR1 known ✓ Q99720 1/20 0.34
PPARG known ✓ P37231 1/20 0.34
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 2/20 0.37
KDM1A O60341 5/20 0.35
MEN1 O00255 1/20 0.34
NR2E3 Q9Y5X4 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6472053 0.99 ACHE (0.38) ACHECYP1A2CYP2C9CYP2C19KMT2A
Hydrochloric Acid SCHEMBL11898398 0.82 CYP1A2 (0.38) CYP1A2CYP2C9CYP2C19KMT2AKDM1A
SCHEMBL16192661 0.76 HDAC9 (0.35) KMT2ASIGMAR1
SCHEMBL4946111 0.75 ACHE (0.41) ACHE
SCHEMBL2028968 0.73 SIGMAR1 (0.38) CYP1A2CYP2C9CYP2C19KMT2ASIGMAR1
SCHEMBL1051970 0.69 MAOB (0.39) ACHEKMT2AKDM1AMEN1SIGMAR1
SCHEMBL4348712 0.65 MAOB (0.38) ACHEKDM1ASIGMAR1
SCHEMBL7341859 0.63 MAOB (0.38) ACHECYP1A2CYP2C9CYP2C19KDM1A
SCHEMBL5807645 0.63 KDM1A (0.40) ACHEKMT2AKDM1AMEN1SIGMAR1
SCHEMBL7947368 0.63 MAOB (0.41) ACHECYP1A2CYP2C9CYP2C19KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1686973-A4 COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES TECHNION RES & DEV FOUNDATION (IL) 2009-03-25 EP claimed
EP-1942881-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE Technion Research and Development of Foundation, Ltd. (IL) 2008-07-16 EP claimed
US-20080090915-A1 METHOD FOR PREVENTING OR ATTENUATING ANTHRACYCLINE-INDUCED CARDIOTOXICITY TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2008-04-17 US claimed
WO-2007039909-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2007-04-12 WO claimed
US-20060287401-A1 Methods for treatment of cardiovascular disorders and diseases TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2006-12-21 US claimed
EP-1686973-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) 2006-08-09 EP claimed
WO-2005051371-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2005-06-09 WO claimed
US-6303650-B1 FOR THERAPY OF ALZHEIMER'S DISEASE OR DEMENTIA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2001-10-16 US claimed
EP-2433626-B1 Compositions and methods for treatment of cardiovascular disorders and diseases TECHNION RES & DEV FOUNDATION (IL) 2015-11-04 EP disclosed
US-8263655-B2 Methods for treatment of renal failure TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD (IL) 2012-09-11 US disclosed
US-20120095107-A1 METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) 2012-04-19 US disclosed
EP-2433626-A1 Compositions and Methods for Treatment of Cardiovascular Disorders and Diseases Technion Research & Development Foundation Ltd. (IL) 2012-03-28 EP disclosed
US-8097608-B2 Use of propargylamine or derivative including including N-propargyl-1-aminoindane as protective agent; preventing apoptosis TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2012-01-17 US disclosed
EP-1686973-A4 COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES TECHNION RES & DEV FOUNDATION (IL) 2009-03-25 EP disclosed
US-20070082958-A1 Methods for treatment of renal failure TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2007-04-12 US disclosed
WO-2007039909-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2007-04-12 WO disclosed
US-20060287401-A1 Methods for treatment of cardiovascular disorders and diseases TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2006-12-21 US disclosed
EP-1686973-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) 2006-08-09 EP disclosed
US-20050171210-A1 Compositions and methods for treatment of cardiovascular disorders and diseases TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2005-08-04 US disclosed
WO-2005051371-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2005-06-09 WO disclosed